ProAssurance (PRA) Expected to Announce Earnings on Thursday

Key Points

• ProAssurance is projected to announce its Q2 2025 earnings on August 14th, with expected earnings of $0.20 per share and revenues of $265.80 million.
• The company reported $0.52 earnings per share for the last quarter, exceeding analysts' estimates and marking a year-over-year revenue decline of 19.9%.
• ProAssurance has seen interest from hedge funds, with notable increases in holdings from firms like AQR Capital Management and Goldman Sachs, highlighting increased institutional investment in the stock.

ProAssurance (NYSE:PRA - Get Free Report) is anticipated to post its Q2 2025 quarterly earnings results before the market opens on Thursday, August 14th. Analysts expect ProAssurance to post earnings of $0.20 per share and revenue of $265.80 million for the quarter.

ProAssurance (NYSE:PRA - Get Free Report) last released its earnings results on Tuesday, August 5th. The insurance provider reported $0.52 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.19 by $0.33. The firm had revenue of $271.94 million during the quarter, compared to analyst estimates of $266.72 million. ProAssurance had a return on equity of 5.62% and a net margin of 4.33%. ProAssurance's revenue was down 19.9% compared to the same quarter last year. During the same period last year, the business posted $0.23 earnings per share. On average, analysts expect ProAssurance to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

ProAssurance Stock Up 0.1%

NYSE:PRA traded up $0.03 during midday trading on Friday, reaching $23.92. The company had a trading volume of 402,847 shares, compared to its average volume of 590,802. The firm has a market capitalization of $1.23 billion, a price-to-earnings ratio of 25.44 and a beta of 0.13. The stock's fifty day simple moving average is $23.41 and its 200-day simple moving average is $21.00. ProAssurance has a 12-month low of $12.05 and a 12-month high of $24.00. The company has a current ratio of 0.26, a quick ratio of 0.26 and a debt-to-equity ratio of 0.33.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on PRA. Piper Sandler lifted their target price on ProAssurance from $18.00 to $25.00 and gave the company a "neutral" rating in a report on Thursday, May 8th. Wall Street Zen began coverage on ProAssurance in a report on Monday, May 19th. They issued a "hold" rating for the company. One research analyst has rated the stock with a sell rating and five have issued a hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $21.50.

Hedge Funds Weigh In On ProAssurance

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Acadian Asset Management LLC purchased a new stake in shares of ProAssurance during the 1st quarter worth approximately $237,000. Jones Financial Companies Lllp purchased a new stake in shares of ProAssurance during the 1st quarter worth approximately $600,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of ProAssurance by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,293 shares of the insurance provider's stock worth $707,000 after acquiring an additional 1,302 shares in the last quarter. Jane Street Group LLC boosted its stake in shares of ProAssurance by 70.0% during the 1st quarter. Jane Street Group LLC now owns 72,944 shares of the insurance provider's stock worth $1,703,000 after acquiring an additional 30,028 shares in the last quarter. Finally, AQR Capital Management LLC boosted its stake in shares of ProAssurance by 40.4% during the 1st quarter. AQR Capital Management LLC now owns 134,641 shares of the insurance provider's stock worth $3,144,000 after acquiring an additional 38,756 shares in the last quarter. Institutional investors and hedge funds own 85.58% of the company's stock.

About ProAssurance

ProAssurance Corporation, through its subsidiaries, provides property and casualty insurance, and reinsurance products in the United States. The company operates through Specialty Property and Casualty, Workers' Compensation Insurance, and Segregated Portfolio Cell Reinsurance segments. It offers professional liability insurance to healthcare providers and institutions, and attorneys and their firms; medical technology liability insurance to medical technology and life sciences companies; and custom alternative risk solutions, including assumed reinsurance, loss portfolio transfers, and captive cell programs for healthcare professional liability insureds.